First-in-human randomized placebo-controlled ascending-dose study of JNJ-63733657 in healthy adults and adults with prodromal or mild Alzheimer's disease

Phase 1, randomised, double-blind trial of posidinemab in Alzheimer's disease (AD) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability after single ascending intravenous dose in healthy subjects and Safety and tolerability after multiple ascending intravenous doses in prodromal or mild Alzheimer's disease. Started Jan 2018; status: completed.